Key result
Low-dose aspirin (0.45 mg/kg/day) produced near maximal (90%) inhibition of platelet thromboxane generation in type II hyperlipoproteinemic subjects, similar to high-dose aspirin.
Why the study?
Does low-dose aspirin effectively inhibit platelet function in type II hyperlipoproteinemic subjects compared to high-dose aspirin?
Does low-dose aspirin effectively inhibit platelet function in type II hyperlipoproteinemic subjects compared to high-dose aspirin?
Low-dose aspirin is sufficient to inhibit platelet function in type II hyperlipoproteinemic patients, indicating they do not require higher doses.
Answers are grounded in this paper and cite their sources.
May support low-dose aspirin in type II hyperlipoproteinemia; leaves open confirmation in outcome trials.
• Low-dose aspirin may be inadequate for inhibition of platelet function in hyperlipoproteinemics due to increased platelet reactivity. Platelet function was studied in 18 type II hyperlipoproteinemic and 12 normal subjects after at least ten days of treatment with placebo and with low-dose (0.45 mg/kg/day) and high-dose (900 mg/day) aspirin. In the normal and hyperlipoproteinemic subjects, low-dose aspirin produced near maximal (90%) inhibition of platelet thromboxane generation, significant prolongation of the bleeding time, and significant inhibition of platelet aggregation, similar in degree to the inhibition produced by high-dose aspirin. There was no significant difference between hyperlipoproteinemic and normal subjects in any of the platelet function measures before and after aspirin treatment. Thus, a daily 0.45-mg/kg aspirin dose (20 to 45 mg) effectively inhibited platelet function in type II hyperlipoproteinemics, who do not appear to have an increased dose requirement for aspirin. (Arch Intern Med1986;146:921-925)
No takes yet. Share an insight, caveat, or question.
Marjorie L. Zucker (1986) studied Type II hyperlipoproteinemia (n=30). Low-dose aspirin vs. Placebo and high-dose aspirin (900 mg/day) was evaluated on Inhibition of platelet thromboxane generation. Low-dose aspirin (0.45 mg/kg/day) produced near maximal (90%) inhibition of platelet thromboxane generation in type II hyperlipoproteinemic subjects, similar to high-dose aspirin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: